Discovery of the Anticancer Mechanism of (EE)-bisantrene
Released
Released
Announcement PDF
Race Oncology Ltd • ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com
ASX Announcement
Primary Anticancer Mechanism of Action of (E,E)-bisantrene
discovered to be from binding to G4-DNA and RNA sites
● (E,E)-bisantrene (RCDS1) discovered act by binding to G4-DNA & RNA structures and
is not a doxorubicin-like chemotherapeutic
● Targeting G4-DNA & RNA reduces the activity of many important cancer genes
(including the master gene regulator MYC), inhibits topoisomerase 2 and telomerase,
and indirectly increases the level of m6
A in RNA
● The discovery of the G4-targeting mechanism of action of RCDS1 has important
clinical and commercial implications.
2 October 2025 – Race Oncology Limited (“Race”) is pleased to announce the discovery of the primary
mechanism of action (MOA) of (E,E)-bisantrene (RCDS1). Scientific studies undertaken by Race Oncology
and collaborators have identified the anticancer activity of RCDS1 predominantly results from binding and
stabilising of important regulatory DNA and RNA structures called G-quadruplexes (G4) which found
throughout the human genome (Figure 1). G4 sequences form 3-dimensional structures that regulate the
expression and translation of many genes involved in causing cancer (oncogenes), including the master
cancer growth regulator, MYC. In addition, the stabilisation of G4-DNA and RNA structures inhibits the
enzymes topoisomerase 2 and telomerase, and indirectly increases the level of m6
A in RNA, mimicing the
enzymatic inhibition of the fat mass and obesity-associated protein (FTO).
Figure 1. Model of RCDS1 (E,E-bisantrene) binding to the G4 DNA structure found within the promotor region of MYC.
Race Oncology CEO and Managing Director, Dr Daniel Tillett commented, “The discovery (E,E)-bisantrene
acts primarily by binding to G4-DNA and RNA structures, and not like the chemotherapeutic doxorubicin,
fundamentally changes our thinking on how to best use this drug in the clinic. Bisantrene continues to
surprise, and we look forward to building on this mechanism of action discovery in our future clinical and
commercial plans.”
Race Oncology Ltd • ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com
Prior assumed mechanism of action of bisantrene
Bisantrene has long been assumed to be a DNA targeting chemotherapeutic anticancer drug like the
widely used anthracyclines (e.g. doxorubicin). There was little data to support this hypothesis beyond early
studies showing bisantrene binds to double-stranded DNA and inhibits DNA replication and RNA
transcription1
. While it was noted in the scientific literature that bisantrene behaved differently to the
anthracyclines (most notably in causing minimal-to-no cardiotoxicity), the limited understanding of how
all anticancer drugs worked at a molecular level in the 1980s made determining the true MOA of
bisantrene difficult2
. The conclusion of the clinical development of bisantrene by Lederle Laboratories in
1988 effectively ended most scientific interest in studying how bisantrene works as an anticancer agent.
New studies into the molecular mechanism of action of (E,E)-bisantrene
Race Oncology began an active program to explore how (E,E)-bisantrene works using modern science. In
the first stage, RCDS1 was studied across a large and diverse panel of cancer cells using an extensive array
of both historical and modern anticancer drugs. The rationale for this analysis is that mechanistically
similar drugs cluster together, enabling an unbiased grouping of a drugs by mechanism of action. As shown
in Figure 2, RCDS1 did not cluster with the well-known anthracyclines, but instead aligned with a range of
unexpected drugs, including the G4-DNA binding agent, actinomycin D.
Figure 2. Cluster analysis of the anticancer responses of 195 drugs across 102 cancer cell lines showing that RCDS1 (E,E-
bisantrene) is similar in mechanism of action to the G4-DNA binding drug actinomycin D.
This early result, together with an extensive review of the scientific literature, led Race to initiate a series
of studies exploring the binding of RCDS1 to G4-DNA and RNA regions and downstream anticancer effects.
Primary mechanism of action of (E,E)-bisantrene discovered to be via G4-DNA
and RNA binding
The Race preclinical team and other investigators3
uncovered G4-binding drugs like RCDS1 exert their
anticancer activity through a range of downstream effects including: inhibiting telomerase4
, inhibiting
topoisomerase II and generating double-stranded DNA breaks5
, DNA hypomethylation6
, increasing m6
A
levels in RNA, and reducing the activity of many important cancer genes such as MYC (Figures 3 & 5).
Race Oncology Ltd • ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com
Figure 3. Binding of RCDS1 to G4-DNA and RNA structures causes multiple downstream anticancer effects.
This broad activity is shared with other G4-DNA binding drugs which are known to regulate the expression
of cancer genes that contain G-quadruplex within their promoter regions, including MYC, c-KIT, KRAS,
TERT, EGFR, BCL2, VEGF, HIF1A, MYB and PDGFA (reviewed in Collie et al.).7
Importance of MYC in cancer growth and progression
The MYC protein acts as a master switch that controls the expression of many genes involved in a myriad
of physiological processes, such as cell growth, differentiation, survival, metabolic reprogramming, cell
adhesion, angiogenesis, chemotherapy resistance, and immune surveillance.8
The MYC gene is genetically
activated and/or overexpressed through gene amplification, chromosomal translocation, or mutation in
over 70% of human cancers, making it a central driver of cancer growth, therapy resistance, and
proliferation.9
Despite extensive efforts from the pharmaceutical industry to target MYC directly with small molecule
drugs, this has proven an intractable challenge because the important functional domains of MYC protein
are intrinsically disordered and lack a targetable active site. In addition, the high affinity interaction
between MYC and its obligate protein binding partner MAX, along with the partial functional redundancy
of the different MYC family members and their nuclear localisation, have posed an enduring obstacle for
the development of effective MYC-inhibiting cancer drugs.10
Race Oncology Ltd • ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com
The MYC gene promoter region contains one of the most extensively studied DNA G-quadruplexes. Hurley
and coworkers first reported MYC gene expression can be greatly decreased by the binding of a G-
quadruplex stabilising small molecule ligand.11
Additional G-quadruplex binding ligands have since been
shown to reduce MYC gene expression, overcome anticancer therapy resistance, and slow cancer cell
growth (Figure 4).12,13
Figure 4. Ligand binding to the MYC gene G4 promoter region causes a downregulation of MYC expression resulting in
reduced oncogenic signalling, cancer growth and anticancer therapy resistance.
Importantly, studies conducted by Race have found that potent downregulation of the MYC gene occurs
shortly after treatment with RCDS1 (Figure 5). This MYC-targeting has also been observed in other cancer
cell types.14
Figure 5. Expression of the MYC gene is dose-dependently downregulated by RCDS1 in MDA-MB-231 breast cancer cells.
G-quadruplexes and the m6
A RNA regulatory system
The level of the modified nucleotide m6
A in RNA has been found to play an important role in a wide range
of diseases, such as obesity, heart disease, type 2 diabetes and cancer.15
Cellular m6
A RNA levels are
regulated by the relative activities of the METTL3/METTL14 m6
A RNA methylase complex (m6
A writers)
and the FTO and ALKBH5 m6
A RNA demethylation enzymes (m6
A erasers)(Figure 6).16
While a complex
and still developing field, decreases in m6
A levels have been associated with cancer treatment resistance
and disease aggressiveness.17
10 100 1000 10000
0
50
100
150
RCDS1 (nM)
MYC
Expression
(%)
EC50: 322.5 + 42.6 nM
Race Oncology Ltd • ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com
Figure 6. Levels of m6A in RNA provide multifaceted regulation of gene expression. m6A levels affect transcription,
alternative splicing, alternative polyadenylation, nuclear export, cap-dependent and cap-independent translation, mRNA
degradation, and mRNA stabilisation. A diverse set of reader proteins that selectively bind m6A, either directly or indirectly,
mediate the many effects on gene expression.
Intriguingly, G-quadruplexes have been found to indirectly regulate the levels of m6
A in RNA via two
separate mechanisms. Firstly, the expression of FTO and ALKBH5 is regulated by MYC, such that
downregulation of MYC reduces the expression of these two demethylases, leading to a corresponding
increase in RNA m6
A levels and vice versa.18
Secondly, the binding of the METTL3/METTL14 methylation complex to RNA is controlled by G4-RNA sites
within RNA transcripts. Molecules that increase the stability of G4-RNA structures increase the binding of
the methylation complex to RNA, and hence the methylation rate and level of m6
A found in RNA.19
Importantly, both these indirect mechanisms can mimic at a cellular level the increases in m6
A that are
seen from direct enzymatic inhibition of the RNA demethylases FTO and ALKBH5.
Clinical & commercial significance
The discovery of the primary anticancer mechanism of action of RCDS1 provides several benefits. Knowing
how an anticancer drug works at the molecular level makes it much simpler to identify the cancer types
(or sub-types) that are most likely to respond to the drug. This knowledge extends to aiding the
identification of drug combinations that are likely to be synergistic when used together. Rather than
having to blindly test millions of possible combinations of different drugs in hundreds of cancer types,
knowing the MOA allows the rational selection of the likely best drug combinations and cancers to treat.
Regulators prefer the MOA of new drugs to be included in regulatory submissions since it improves patient
safety by helping predict side effects, guides appropriate use, and identifies the patients most likely to
benefit.
An important additional benefit to knowing the MOA of RCDS1 is it enables the development of
pharmacodynamic biomarker tests that are predictive of a patient’s response to treatment. New cancer
drugs with an associated biomarker test are more than twice as likely to obtain regulatory approval.20
Finally, understanding the MOA of a drug increases the probability of successful pharma partnering – put
simply, large pharma has an expectation that their partners understand how any new drug works because
this reduces scientific and clinical risk, improves trial design, and aligns with regulatory expectations.
Race Oncology Ltd • ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com
Next steps
• Additional preclinical studies exploring the G4-DNA and RNA binding effects of RCDS1 on
anticancer efficacy and treatment resistance modification.
• Further investigations to identify the major cancer indication(s) most suited to RCDS1 use and the
best drug combinations to explore in the clinic.
• Identification of the most valuable commercial market opportunity for RCDS1 and the clinical
trials required.
• Publication of the mechanism of actions studies in peer reviewed scientific journals and/or
presentation at major international conferences.
Race management will host a webinar explaining the significance of this discovery on Wednesday,
8 October, 2025 at 6 pm AEST. To register for this webinar please use the following link:
https://us02web.zoom.us/webinar/register/WN_mZs08BT8SDC4V9I2eTLbgA
References
1. Von Hoff, D. D., Coltman, C. A. & Forseth, B. Activity of 9–10 anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-
yl)hydrazone]dihydrochloride (CL216,942) in a human tumor cloning system. Cancer Chemother. Pharmacol. 6, 141–144 (1981).
2. Poduri, R. Drug Discovery and Development, From Targets and Molecules to Medicines. 1–10 (2021).
3. M. Folini, C. Pivetta, G. Zagotto, C.D. Marco, M. Palumbo, N. Zaffaroni, C. Sissi, Remarkable interference with telomeric function by a G-
quadruplex selective bisantrene regioisomer, Biochem. Pharmacol. 79 (2010) 1781–1790.
4. P.J. Perry, A.P. Reszka, A.A. Wood, M.A. Read, S.M. Gowan, H.S. Dosanjh, J.O. Trent, T.C. Jenkins, L.R. Kelland, S. Neidle, Human
Telomerase Inhibition by Regioisomeric Disubstituted Amidoanthracene-9,10-diones, J. Med. Chem. 41 (1998) 4873–4884.
5. G. Zagotto, A. Oliva, F. Guano, E. Menta, G. Capranico, M. Palumbo, Synthesis, DNA-damaging and cytotoxic properties of novel
topoisomerase II-directed bisantrene analogues, Bioorg. Med. Chem. Lett. 8 (1998) 121–126.
6. Mao, S.-Q. et al. DNA G-quadruplex structures mold the DNA methylome. Nat. Struct. Mol. Biol. 25, 951–957 (2018).
7. G.W. Collie, G.N. Parkinson, The application of DNA and RNA G-quadruplexes to therapeutic medicines, Chem. Soc. Rev. 40 (2011) 5867–
5892.
8. S.C. Casey, V. Baylot, D.W. Felsher, MYC: Master Regulator of Immune Privilege, Trends Immunol. 38 (2017) 298–305.
9. H. Chen, H. Liu, G. Qing, Targeting oncogenic Myc as a strategy for cancer treatment, Signal Transduct. Target. Ther. 3 (2018).
10. Llombart, V. & Mansour, M. R. Therapeutic targeting of “undruggable” MYC. EBioMedicine 75, 103756 (2022).
11. A. Siddiqui-Jain, C.L. Grand, D.J. Bearss, L.H. Hurley, Direct evidence for a G-quadruplex in a promoter region and its targeting with a
small molecule to repress c-MYC transcription, Proc. Natl. Acad. Sci. 99 (2002) 11593–11598.
12 J.M. Nicoludis, S.T. Miller, P.D. Jeffrey, S.P. Barrett, P.R. Rablen, T.J. Lawton, L.A. Yatsunyk, Optimized End-Stacking Provides Specificity
of N-Methyl Mesoporphyrin IX for Human Telomeric G-Quadruplex DNA, J. Am. Chem. Soc. 134 (2012) 20446–20456.
13. T.-M. Ou, Y.-J. Lu, C. Zhang, Z.-S. Huang, X.-D. Wang, J.-H. Tan, Y. Chen, D.-L. Ma, K.-Y. Wong, J.C.-O. Tang, A.S.-C. Chan, L.-Q. Gu,
Stabilization of G-Quadruplex DNA and Down-Regulation of Oncogene c-myc by Quindoline Derivatives, J. Med. Chem. 50 (2007) 1465–
1474.
14. R. Su, L. Dong, Y. Li, M. Gao, L. Han, M. Wunderlich, X. Deng, H. Li, Y. Huang, L. Gao, C. Li, Z. Zhao, S. Robinson, B. Tan, Y. Qing, X. Qin, E.
Prince, J. Xie, H. Qin, W. Li, C. Shen, J. Sun, P. Kulkarni, H. Weng, H. Huang, Z. Chen, B. Zhang, X. Wu, M.J. Olsen, M. Müschen, G. Marcucci,
R. Salgia, L. Li, A.T. Fathi, Z. Li, J.C. Mulloy, M. Wei, D. Horne, J. Chen, Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune
Evasion, Cancer Cell 38 (2020) 79-96.e11.
15. Q. Lan, P.Y. Liu, J. Haase, J.L. Bell, S. Hüttelmaier, T. Liu, The Critical Role of RNA m6A Methylation in Cancer, Cancer Res. 79 (2019)
1285–1292.
16. I. Barbieri, T. Kouzarides, Role of RNA modifications in cancer, Nat. Rev. Cancer 20 (2020) 303–322.
17. C.P. Rabolli, F. Accornero, m6A RNA methylation: a dynamic regulator of cardiac muscle and extracellular matrix, Curr. Opin. Physiol. 28
(2022) 100561.
18. Wu, G. et al. MYC promotes cancer progression by modulating m6A modifications to suppress target gene translation. EMBO Rep. 22,
EMBR202051519 (2021).
19. Yoshida, A., Oyoshi, T., Suda, A., Futaki, S. & Imanishi, M. Recognition of G-quadruplex RNA by a crucial RNA methyltransferase
component, METTL14. Nucleic Acids Res. 50, 449–457 (2021).
20. Parker, J. L. et al. Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis. Cancer Med. 10, 1955–1963
(2021).
-ENDS-
Race Oncology Ltd • ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com
Q&A
Why did it take Race so long to discover (E,E)-bisantrene (RCDS1) was a G4-
binding drug?
Science is hard. The anticancer effects of RCDS1 are varied and highly complex, making identification of
the underlying mechanism of action neither easy nor straightforward. The last 40 years have seen massive
advances in molecular biology and cancer research and have enabled what was an impossible task in the
1980s to be possible today. A contributing factor is that the significant resources required to understand
the mechanism of action of RCDS1 were only committed by Race in the last couple of years.
The model of RCDS1 bound to the G4-DNA structure shows the molecule in the
(E,E)-configuration. Is this why only the (E,E)-bisantrene isomer is active?
Excellent question. The answer is we don’t know yet why the (E,Z)-form of bisantrene has little to no
anticancer activity, but the idea that the (E,Z)-isomer could have reduced binding to G4-structures from
the orientation of the Z-side chain is plausible. This hypothesis is currently being explored by the Race
team and collaborators.
What is MYC? Why is it important in cancer?
MYC acts as a master on-off switch for cell growth and division, activating the production of numerous
proteins that drive the cell to divide. In normal cells, the job of MYC is to help control how quickly cells
grow, copy their DNA, and divide. It is tightly regulated, turning on only when the body needs new cells
for growth, repair, or immune responses, and switches off when it is no longer needed.
In cancer, MYC becomes overactive, and regulation is lost. As a result, MYC drives cancer cells to divide
uncontrollably and alters their metabolism to support rapid tumour growth. MYC is overexpressed or
dysregulated in around 70% of cancers making it one of the most important targets for new anticancer
treatments.
Why are there no drugs that specifically target MYC in the clinic?
MYC has been considered undruggable despite decades of research conducted by the pharmaceutical
industry. In general, most successful drugs bind to specific pockets that exist in the target protein
structure, much like how a key fits into a lock. The functional parts of the MYC protein are unstructured
and lack drug binding pockets. This has hampered efforts to find potent MYC-inhibiting drugs despite a
great deal of scientific effort.
Are there other G-quadruplex binding drugs?
Yes, but only a few. To bind to a G-quadruplex structure well, molecules must have a flat aromatic core
structure with charged and flexible side groups. Unfortunately, such structures often confer poor drug-
like properties (e.g. solubility, pharmacokinetics, tissue distribution etc.). Indeed poor solubility was a
major problem with bisantrene since the 1980s and only extensive efforts by Race to develop the RC220
formulation made it a viable drug.
The two best known G-quadruplex drugs in the clinic are CX-5461 (pidnarulex) and QN-302. Both are only
in early clinical development for oncology indications.
Race Oncology Ltd • ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com
Are all G-quadruplex binding drugs similar in activity?
No. There are more than 80 different G-quadruplex structures known depending on the DNA or RNA
sequences from which they are formed. Each G4-targteting drug binds to only a subset of the possible G4-
structures found in the human genome, resulting in a wide variation in activity of the different drugs.
Why has nothing been mentioned about the cardioprotection mechanism of
action in this announcement?
This announcement is an update on discoveries made into the anticancer mechanism of action of RCDS1,
not its cardioprotective properties. Additional data will be presented by Race CEO Dr Daniel Tillett at the
European Society of Medical Oncology (ESMO) Annual Conference being held from the 18th
to 21st
of
October 2025. Shareholders can expect further announcements after this work is presented at ESMO.
Is there a video explaining these amazing discoveries?
Yes. Dr Pete Smith, Race Executive Chair, has recorded a short video which is available on the Race Investor
Hub pages: https://announcements.raceoncology.com/link/PGqJze
Please summarise all this complex science. What do I really need to know?
There are three key takeaways from this announcement.
1. We now know how RCDS1 works as an anticancer drug – it isn’t an old chemo drug like
doxorubicin.
2. Knowing how RCDS1 works allows us to find the best possible uses for RC220 and help more
cancer patients sooner.
3. The potent effects of RCDS1 on the master cancer growth regulator MYC is very important, both
clinically and commercially.
Race Oncology Ltd • ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com
About Race Oncology (ASX: RAC)
Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated
mission to be at the heart of cancer care.
Race’s lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent primarily functioning via
G4-binding. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised
safety profile.
Race is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients
across multiple oncology indications, with a clinical focus on combinations with an anthracycline
(doxorubicin), where we aim to deliver both cardioprotection and enhanced anticancer activity in solid
tumour indications. Race is also exploring the use of RC220 as a low intensity treatment for acute myeloid
leukaemia and other cancers.
Race Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine,
University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence
agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with
cancer across the world.
Learn more at www.raceoncology.com.
If you have any questions on this announcement or any past Race Oncology announcements, please go to
the Interactive Announcements page in our Investor Hub announcements.raceoncology.com
Race encourages all investors to go paperless by registering their details with the Company’s share registry,
Automic Registry Services, at www.automicgroup.com.au.
Release authorised by:
Daniel Tillett, CEO
info@raceoncology.com
Media contact:
Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au
Share your feedback
Discover